{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Congenital+Defects&page=69",
    "query": {
      "condition": "Congenital Defects",
      "page": 69
    },
    "page_size": 10
  },
  "pagination": {
    "page": 69,
    "page_size": 10,
    "total_count": 10850,
    "total_pages": 1085,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Congenital+Defects&page=70&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Congenital+Defects&page=68&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-21T00:55:39.264Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02161380",
      "title": "Safety Study of an Adeno-associated Virus Vector for Gene Therapy of Leber's Hereditary Optic Neuropathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leber's Hereditary Optic Neuropathy"
      ],
      "interventions": [
        {
          "name": "injection of scAAV2-P1ND4v2 1.18x10e9 vg (Low),",
          "type": "DRUG"
        },
        {
          "name": "injection of scAAV2-P1ND4v2 5.81 X10e9 vg (Med)",
          "type": "DRUG"
        },
        {
          "name": "injection of scAAV2-P1ND4v2 2.4 X10e10vg (High)",
          "type": "DRUG"
        },
        {
          "name": "injection of scAAV2-P1ND4v2 1.0 X10e11vg (Higher)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Byron Lam",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2014-07-14",
      "completion_date": "2025-03-31",
      "has_results": true,
      "last_update_posted_date": "2025-06-05",
      "last_synced_at": "2026-11-21T00:55:39.264Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02161380"
    },
    {
      "nct_id": "NCT02857023",
      "title": "Feasibility and Efficacy of a Home-based, Computerized Cognitive Training Program in Pediatric Sickle Cell Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Anemia, Sickle Cell"
      ],
      "interventions": [
        {
          "name": "Cogmed RM",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Steven J. Hardy",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "7 Years to 16 Years"
      },
      "enrollment_count": 91,
      "start_date": "2014-10",
      "completion_date": "2018-08",
      "has_results": false,
      "last_update_posted_date": "2018-11-23",
      "last_synced_at": "2026-11-21T00:55:39.264Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02857023"
    },
    {
      "nct_id": "NCT03472040",
      "title": "A Long Term Safety Study of BCX7353 in Hereditary Angioedema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Hereditary Angioedema",
        "HAE",
        "Prophylaxis"
      ],
      "interventions": [
        {
          "name": "BCX7353",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioCryst Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 387,
      "start_date": "2018-02-16",
      "completion_date": "2022-04-27",
      "has_results": true,
      "last_update_posted_date": "2023-06-18",
      "last_synced_at": "2026-11-21T00:55:39.264Z",
      "location_count": 42,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Bentonville, Arkansas + 39 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Bentonville",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03472040"
    },
    {
      "nct_id": "NCT00056550",
      "title": "Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of Recombinant Human Antithrombin (rhAT) to Hereditary Antithrombin(AT) Deficient Patients in High Risk Situations.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Antithrombin Deficiency, Congenital"
      ],
      "interventions": [
        {
          "name": "Recombinant Human Antithrombin (rhAT)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "rEVO Biologics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 14,
      "start_date": "2002-12",
      "completion_date": "2004-02",
      "has_results": true,
      "last_update_posted_date": "2012-10-16",
      "last_synced_at": "2026-11-21T00:55:39.264Z",
      "location_count": 2,
      "location_summary": "Marietta, Georgia • Charleston, South Carolina",
      "locations": [
        {
          "city": "Marietta",
          "state": "Georgia"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00056550"
    },
    {
      "nct_id": "NCT05188274",
      "title": "A Clinical Study to Evaluate the Safety and Efficacy of T92 in Pediatric Patients With Tourette Syndrome",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Tourette Syndrome in Children",
        "Tourette Syndrome in Adolescence"
      ],
      "interventions": [
        {
          "name": "T92",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Tasly Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 150,
      "start_date": "2022-05",
      "completion_date": "2024-10",
      "has_results": false,
      "last_update_posted_date": "2022-01-12",
      "last_synced_at": "2026-11-21T00:55:39.264Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05188274"
    },
    {
      "nct_id": "NCT01942590",
      "title": "Safety and Efficacy of Clenbuterol in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Pompe Disease"
      ],
      "interventions": [
        {
          "name": "Clenbuterol",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dwight Koeberl, M.D., Ph.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2013-09",
      "completion_date": "2016-09-02",
      "has_results": true,
      "last_update_posted_date": "2019-07-02",
      "last_synced_at": "2026-11-21T00:55:39.264Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01942590"
    },
    {
      "nct_id": "NCT03648710",
      "title": "Community Health Workers and mHealth for Sickle Cell Disease Care",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Peer Community Health Worker",
          "type": "OTHER"
        },
        {
          "name": "Mobile Health",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Children's Hospital of Philadelphia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "17 Years and older"
      },
      "enrollment_count": 405,
      "start_date": "2019-01-15",
      "completion_date": "2024-08-31",
      "has_results": false,
      "last_update_posted_date": "2024-12-04",
      "last_synced_at": "2026-11-21T00:55:39.264Z",
      "location_count": 5,
      "location_summary": "Hartford, Connecticut • New Hyde Park, New York • Cincinnati, Ohio + 1 more",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "New Hyde Park",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03648710"
    },
    {
      "nct_id": "NCT04046224",
      "title": "Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Fabry Disease"
      ],
      "interventions": [
        {
          "name": "ST-920",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sangamo Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2019-07-23",
      "completion_date": "2025-04-10",
      "has_results": true,
      "last_update_posted_date": "2026-10-27",
      "last_synced_at": "2026-11-21T00:55:39.264Z",
      "location_count": 9,
      "location_summary": "Irvine, California • Tampa, Florida • Atlanta, Georgia + 6 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04046224"
    },
    {
      "nct_id": "NCT04990440",
      "title": "A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dermatitis, Atopic"
      ],
      "interventions": [
        {
          "name": "Bermekimab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 6,
      "start_date": "2021-09-02",
      "completion_date": "2022-03-09",
      "has_results": true,
      "last_update_posted_date": "2023-05-24",
      "last_synced_at": "2026-11-21T00:55:39.264Z",
      "location_count": 6,
      "location_summary": "Indianapolis, Indiana • Chesterfield, Michigan • Tulsa, Oklahoma + 2 more",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Chesterfield",
          "state": "Michigan"
        },
        {
          "city": "Tulsa",
          "state": "Oklahoma"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04990440"
    },
    {
      "nct_id": "NCT00093418",
      "title": "S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Acute Megakaryoblastic Leukemia (M7)",
        "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)",
        "Adult Acute Monoblastic Leukemia (M5a)",
        "Adult Acute Monocytic Leukemia (M5b)",
        "Adult Acute Myeloblastic Leukemia With Maturation (M2)",
        "Adult Acute Myeloblastic Leukemia Without Maturation (M1)",
        "Adult Acute Myeloid Leukemia in Remission",
        "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities",
        "Adult Acute Myeloid Leukemia With Del(5q)",
        "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)",
        "Adult Acute Myelomonocytic Leukemia (M4)",
        "Adult Erythroleukemia (M6a)",
        "Adult Pure Erythroid Leukemia (M6b)",
        "Recurrent Adult Acute Myeloid Leukemia",
        "Untreated Adult Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "tipifarnib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "70 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "70 Years and older"
      },
      "enrollment_count": 296,
      "start_date": "2004-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-15",
      "last_synced_at": "2026-11-21T00:55:39.264Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00093418"
    }
  ]
}